Lung Therapeutics gathers $14.3 mln Series B
Austin, Texas-based Lung Therapeutics Inc, a clinical stage pharmaceutical company, has closed $14.3 million in Series B financing. Bios Partners led the round with participation from return backer, the UT Horizon Fund.
6 June 2017•1 min read
